GLUCOSCAN
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
May 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 2d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
GLUCOSCAN is an injectable small-molecule diagnostic agent approved by Bristol Myers Squibb in 1978. The specific indication and mechanism of action are not publicly detailed in available data. As a legacy diagnostic product, it represents a mature category with limited expansion potential.
LOE Approaching
Product approaching loss of exclusivity with minimal linked job opportunities, indicating a contracting or maintained-care commercial footprint.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
GLUCOSCAN offers limited career growth opportunities given zero linked job openings and approaching loss of exclusivity. This role would be most suitable for professionals seeking specialized diagnostic product knowledge or winding-down portfolio stewardship experience.
Medical Science LiaisonBrand Manager
Worked on GLUCOSCAN at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.